Last reviewed · How we verify
NCT06095544
Enhanced Recovery After Surgery for SPK Transplantation Recipients
NA trial testing Enhanced recovery for SPK recipients in Transplant Complication in 90 participants. Completed in 1 June 2023.
1 December 2022
Quick facts
| Lead sponsor | Second Affiliated Hospital of Guangzhou Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | health services research |
| Enrollment | 90 |
| Start date | 1 January 2021 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Enhanced recovery for SPK recipients
Conditions studied
- Transplant Complication — all drugs for Transplant Complication →
- Diabetic Nephropathy — all drugs for Diabetic Nephropathy →
- Perioperative/Postoperative Complications — all drugs for Perioperative/Postoperative Complications →
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Who can join
Adults 20 to 62, any sex, with Transplant Complication or Diabetic Nephropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
108 patients underwent elective SPK surgery were randomly divided into ERAS group (E) and routine care group (T). The ERAS group was consisted of evidenced-based systematic optimization approaches, while the control group received routine care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06095544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transplant Complication
Currently open trials in the same condition.
- NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
- NCT06186843 — Plant-based Diet for Kidney Transplant Recipients · NA · active not recruiting
- NCT06063213 — Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation · active not recruiting
- NCT05762211 — Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) · Phase 2 · recruiting
- NCT06493812 — Comparison of Clinical Value in the Use of the Fascia Lata and Temporal Muscle Fascia in the Reconstruction of the Dura · NA · recruiting
Other Second Affiliated Hospital of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
- NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
- NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
- NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
- NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06095544 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
- Last refreshed: 23 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing